RevImmune Announces Phase II Trial of the T-Cell Growth Factor...
BETHESDA, Maryland, June 29, 2020 /PRNewswire-AsiaNet/ -- - Under Way in Europe Since May, In Preparation in the U.S.- Designated As An Urgent Public Health National Priority In U.K. RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and c...
Authors: LATEST ASIANET NEWS RELEASES